This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (32)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Adherence  • Alert me on articles by topic

Mapping the Paths to Virologic Failure

Martin Markowitz, MD

JAMA. 2000;283:250-251.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A near-uniformly fatal clinical syndrome, acquired immunodeficiency syndrome (AIDS), has been transformed during the past 5 years into a treatable infectious disease. The availability of potent antiretroviral agents coincided with the ability to measure levels of circulating virus in vivo. When used in tandem, an understanding of human immunodeficiency virus (HIV) replication dynamics in vivo was made possible, forming the scientific basis for the use of combination antiretroviral therapy.¹ However, the treatment of HIV infection remains far from perfect, and new issues arise with regularity. Critical to achieving optimal therapeutic outcomes is an understanding of treatment failure. Early clinical trials of protease inhibitor monotherapy suggested that the pathway to treatment failure was exclusively via drug resistance.^2-3 Viral rebound was thought to reflect failure of all components of a regimen. Furthermore, it was assumed that the absence of resistance-conferring genotypic changes reflected patient nonadherence.

In this issue of . . . [Full Text of this Article]

Author Affiliation: Aaron Diamond AIDS Research Center, Rockefeller University, New York, NY.

RELATED ARTICLES

Mechanisms of Virologic Failure in Previously Untreated HIV-Infected Patients From a Trial of Induction-Maintenance Therapy
Diane Descamps, Philippe Flandre, Vincent Calvez, Gilles Peytavin, Vincent Meiffredy, Gilles Collin, Constance Delaugerre, Sandrine Robert-Delmas, Brigitte Bazin, Jean Pierre Aboulker, Gilles Pialoux, François Raffi, Françoise Brun-Vézinet, and for the Trilège Study Team
JAMA. 2000;283(2):205-211.
ABSTRACT | FULL TEXT  

Drug Susceptibility in HIV Infection After Viral Rebound in Patients Receiving Indinavir-Containing Regimens
Diane V. Havlir, Nick S. Hellmann, Christos J. Petropoulos, Jeannette M. Whitcomb, Ann C. Collier, Martin S. Hirsch, Pablo Tebas, Jean-Pierre Sommadossi, and Douglas D. Richman
JAMA. 2000;283(2):229-234.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pharmacologic Perspectives for Once-Daily Antiretroviral Therapy
Anderson
The Annals of Pharmacotherapy 2004;38:1924-1934.
ABSTRACT | FULL TEXT  

Discordant Outcomes following Failure of Antiretroviral Therapy Are Associated with Substantial Differences in Human Immunodeficiency Virus-Specific Cellular Immunity
Price et al.
J. Virol. 2003;77:6041-6049.
ABSTRACT | FULL TEXT  

HIV therapy: Managing resistance
Wodarz and Nowak
Proc. Natl. Acad. Sci. USA 2000;97:8193-8195.
FULL TEXT